Marcaine (Bupivacaine Hydrochloride)

Bupivacaine hydrochloride blocks voltage‑gated sodium channels on nerve membranes, preventing the initiation and propagation of action potentials. This stabilizes the neuronal membrane and stops nerve impulse transmission, resulting in a reversible loss of sensation in the area where the drug is administered.

The dose of Marcaine is determined by the prescribing clinician based on the specific procedure, patient weight, and the site of administration. Only a qualified healthcare professional should calculate and administer the appropriate amount in accordance with local guidelines and product labeling.

Safety data for bupivacaine hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician after a thorough risk‑benefit assessment.

To order Marcaine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Marcaine (bupivacaine) has a longer duration of action compared with shorter‑acting agents such as lidocaine or mepivacaine, making it suitable for procedures requiring prolonged analgesia. However, its higher potency also demands careful dosing to avoid systemic toxicity, especially cardiovascular and central nervous system effects.

Marcaine should be stored at controlled room temperature, typically between 20 °C and 25 °C, in its original packaging. Protect the product from light and moisture, and keep it out of reach of children. Do not freeze the solution, and discard any vial that appears cloudy or contains particles.

Marcaine is administered by a qualified healthcare professional via infiltration, peripheral nerve block, or epidural injection, depending on the clinical indication. The drug is supplied as a sterile injectable solution and is injected directly into the target tissue or nerve sheath using aseptic technique.

The most serious risks include cardiovascular toxicity (arrhythmias, hypotension), central nervous system toxicity (seizures, respiratory depression), and severe allergic reactions such as anaphylaxis. Prompt recognition and supportive management are essential if signs of systemic toxicity develop.

Marcaine should not be used in patients with a known hypersensitivity to bupivacaine, other amide‑type local anesthetics, or any component of the formulation. Caution is also advised in individuals with significant cardiac conduction disorders, severe liver disease, or those receiving interacting medications that increase the risk of toxicity.